{ "instance": { "f10q0622_silopharma.htm": { "axisCustom": 2, "axisStandard": 15, "contextCount": 161, "dts": { "calculationLink": { "local": [ "silo-20220630_cal.xml" ] }, "definitionLink": { "local": [ "silo-20220630_def.xml" ] }, "inline": { "local": [ "f10q0622_silopharma.htm" ] }, "labelLink": { "local": [ "silo-20220630_lab.xml" ] }, "presentationLink": { "local": [ "silo-20220630_pre.xml" ] }, "schema": { "local": [ "silo-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 493, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 112, "http://silopharma.com/20220630": 39, "http://xbrl.sec.gov/dei/2022": 4, "total": 155 }, "keyCustom": 109, "keyStandard": 236, "memberCustom": 28, "memberStandard": 17, "nsprefix": "silo", "nsuri": "http://silopharma.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://silopharma.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Disposal of the Discontinued Operations of the NFID Business", "role": "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness", "shortName": "Disposal of the Discontinued Operations of the NFID Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Notes Receivable", "role": "http://silopharma.com/role/NotesReceivable", "shortName": "Notes Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Stockholders\u2019 Equity", "role": "http://silopharma.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Concentrations", "role": "http://silopharma.com/role/Concentrations", "shortName": "Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Commitments and Contingencies", "role": "http://silopharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://silopharma.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Tables)", "role": "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables", "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Tables)", "role": "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables", "shortName": "Disposal of the Discontinued Operations of the NFID Business (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Notes Receivable (Tables)", "role": "http://silopharma.com/role/NotesReceivableTables", "shortName": "Notes Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets", "role": "http://silopharma.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Stockholders\u2019 Equity (Tables)", "role": "http://silopharma.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "silo:ScheduleOfMilestonePayments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://silopharma.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "silo:ScheduleOfMilestonePayments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "silo:AssetPurchaseAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Organization and Business (Details)", "role": "http://silopharma.com/role/OrganizationandBusinessDetails", "shortName": "Organization and Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "silo:AssetPurchaseAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share", "role": "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details)", "role": "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails", "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c77", "decimals": "0", "first": true, "lang": null, "name": "silo:EquityInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis", "role": "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable", "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c77", "decimals": "0", "first": true, "lang": null, "name": "silo:EquityInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company\u2019s equity investments, at fair value", "role": "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable", "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company\u2019s equity investments, at fair value", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "silo:AdditionsofEquitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c83", "decimals": "0", "first": true, "lang": null, "name": "silo:PurchasePrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details)", "role": "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails", "shortName": "Disposal of the Discontinued Operations of the NFID Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c83", "decimals": "0", "first": true, "lang": null, "name": "silo:PurchasePrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c84", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of financial data of the company\u2019s gain from sale of the NFID business", "role": "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable", "shortName": "Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of financial data of the company\u2019s gain from sale of the NFID business", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c84", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestReceivableNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "role": "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestReceivableNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "pf0:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c10", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of operating result of discontinued operations of the NFID business", "role": "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable", "shortName": "Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of operating result of discontinued operations of the NFID business", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "pf0:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c10", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Notes Receivable (Details)", "role": "http://silopharma.com/role/NotesReceivableDetails", "shortName": "Notes Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Notes Receivable (Details) - Schedule of notes receivable net", "role": "http://silopharma.com/role/ScheduleofnotesreceivablenetTable", "shortName": "Notes Receivable (Details) - Schedule of notes receivable net", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Stockholders\u2019 Equity (Details)", "role": "http://silopharma.com/role/StockholdersEquityDetails", "shortName": "Stockholders\u2019 Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c122", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of stock options activities", "role": "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable", "shortName": "Stockholders\u2019 Equity (Details) - Schedule of stock options activities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c122", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c125", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of warrant activities", "role": "http://silopharma.com/role/ScheduleofwarrantactivitiesTable", "shortName": "Stockholders\u2019 Equity (Details) - Schedule of warrant activities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c125", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "silo:ConcentrationsRiskPercentage1", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c131", "decimals": "2", "first": true, "lang": null, "name": "silo:ConcentrationsRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Concentrations (Details)", "role": "http://silopharma.com/role/ConcentrationsDetails", "shortName": "Concentrations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "silo:ConcentrationsRiskPercentage1", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c131", "decimals": "2", "first": true, "lang": null, "name": "silo:ConcentrationsRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c134", "decimals": null, "first": true, "lang": "en-US", "name": "silo:EmploymentAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Commitments and Contingencies (Details)", "role": "http://silopharma.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c134", "decimals": null, "first": true, "lang": "en-US", "name": "silo:EmploymentAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "silo:ScheduleOfMilestonePayments", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c153", "decimals": null, "first": true, "lang": "en-US", "name": "silo:Milestone", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Commitments and Contingencies (Details) - Schedule of milestone payments", "role": "http://silopharma.com/role/ScheduleofmilestonepaymentsTable", "shortName": "Commitments and Contingencies (Details) - Schedule of milestone payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "silo:ScheduleOfMilestonePayments", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c153", "decimals": null, "first": true, "lang": "en-US", "name": "silo:Milestone", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "silo:ScheduleOfUMBMinimumRoyaltyPayments", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c153", "decimals": null, "first": true, "lang": "en-US", "name": "silo:YearsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments", "role": "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable", "shortName": "Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "silo:ScheduleOfUMBMinimumRoyaltyPayments", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c153", "decimals": null, "first": true, "lang": "en-US", "name": "silo:YearsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "silo:LicenseFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://silopharma.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "silo:LicenseFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "silo:ScheduleOfShallPayUMB", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c158", "decimals": "0", "first": true, "lang": null, "name": "silo:SponsoredPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Commitments and Contingencies (Details) - Schedule of shall pay UMB fees", "role": "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable", "shortName": "Commitments and Contingencies (Details) - Schedule of shall pay UMB fees", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "silo:ScheduleOfShallPayUMB", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c158", "decimals": "0", "first": true, "lang": null, "name": "silo:SponsoredPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c40", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity (Unaudited)", "role": "http://silopharma.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c40", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://silopharma.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Organization and Business", "role": "http://silopharma.com/role/OrganizationandBusiness", "shortName": "Organization and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Summary of Significant Accounting Policies", "role": "http://silopharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements", "role": "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements", "shortName": "Fair Value of Financial Instruments and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_silopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silopharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "silo_AdditionalNotesReceivableIn2021": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional notes receivable.", "label": "AdditionalNotesReceivableIn2021", "terseLabel": "Additional notes receivable" } } }, "localname": "AdditionalNotesReceivableIn2021", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofnotesreceivablenetTable" ], "xbrltype": "monetaryItemType" }, "silo_AdditionsofEquitySecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions for equity securities.", "label": "AdditionsofEquitySecurities", "terseLabel": "Additions" } } }, "localname": "AdditionsofEquitySecurities", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "silo_AdvanceFromARelatedParty": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advance from a related party.", "label": "AdvanceFromARelatedParty", "terseLabel": "Advance from a related party" } } }, "localname": "AdvanceFromARelatedParty", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "silo_AggregateGrantDateFairValueOfPlacementAgentWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate grant date fair value of placement agent warrants.", "label": "AggregateGrantDateFairValueOfPlacementAgentWarrants", "terseLabel": "Aggregate grant date fair value of placement agent warrants (in Dollars)" } } }, "localname": "AggregateGrantDateFairValueOfPlacementAgentWarrants", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "silo_AggregateIntrinsicValueGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AggregateIntrinsicValueGranted", "terseLabel": "Granted/Forfeited, Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValueGranted", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "monetaryItemType" }, "silo_AggregateOfConvertedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AggregateOfConvertedShares", "terseLabel": "Aggregate of converted shares (in Shares)" } } }, "localname": "AggregateOfConvertedShares", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "silo_AggregateOfNotesReceivablePurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate of notes receivable purchase price.", "label": "AggregateOfNotesReceivablePurchasePrice", "terseLabel": "Aggregate of notes receivable purchase price" } } }, "localname": "AggregateOfNotesReceivablePurchasePrice", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "silo_AgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AgreementDescription", "terseLabel": "Agreement, description" } } }, "localname": "AgreementDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_AgreementShallExpire": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AgreementShallExpire", "terseLabel": "Agreement shall expire" } } }, "localname": "AgreementShallExpire", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "silo_AikidoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AikidoMember", "terseLabel": "Aikido [Member]" } } }, "localname": "AikidoMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "silo_AikidoPharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AikidoPharmaIncMember", "terseLabel": "Aikido Pharma, Inc. [Member]" } } }, "localname": "AikidoPharmaIncMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "silo_AmortizationOfPrepaidStockbasedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amortization of prepaid stock-based compensation\r \n.", "label": "AmortizationOfPrepaidStockbasedCompensation", "terseLabel": "Amortization of prepaid stock-based compensation" } } }, "localname": "AmortizationOfPrepaidStockbasedCompensation", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "silo_AmortizationOfPrepaidStockbasedExpense": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "AmortizationOfPrepaidStockbasedExpense", "terseLabel": "Amortization of prepaid stock-based compensation" } } }, "localname": "AmortizationOfPrepaidStockbasedExpense", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "silo_AssetPurchaseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Purchase Agreement Description.", "label": "AssetPurchaseAgreementDescription", "terseLabel": "Asset purchase agreement, description" } } }, "localname": "AssetPurchaseAgreementDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "silo_BadDebtRecoveryCashPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BadDebtRecoveryCashPayment", "terseLabel": "Bad debt recovery cash payment, description" } } }, "localname": "BadDebtRecoveryCashPayment", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "stringItemType" }, "silo_BadDebtRecoveryExpense": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Bad debt (recovery) expense.", "label": "BadDebtRecoveryExpense", "terseLabel": "Bad debt recovery" } } }, "localname": "BadDebtRecoveryExpense", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "silo_CashPaidDuringThePeriodForAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashPaidDuringThePeriodForAbstract", "terseLabel": "Cash paid during the period for:" } } }, "localname": "CashPaidDuringThePeriodForAbstract", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "silo_CashReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CashReceived", "terseLabel": "Cash received" } } }, "localname": "CashReceived", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_CashSPICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Securities Investor Protection Corporation.", "label": "CashSPICInsuredAmount", "terseLabel": "Securities investor protection corporation" } } }, "localname": "CashSPICInsuredAmount", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_CollectionOnNoteReceivable": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "CollectionOnNoteReceivable", "terseLabel": "Collection on note receivable" } } }, "localname": "CollectionOnNoteReceivable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "silo_CollectionsOnNotesReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CollectionsOnNotesReceivables", "negatedLabel": "Collections on notes receivables" } } }, "localname": "CollectionsOnNotesReceivables", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofnotesreceivablenetTable" ], "xbrltype": "monetaryItemType" }, "silo_ColumbiaUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ColumbiaUniversityMember", "terseLabel": "Columbia University [Member]" } } }, "localname": "ColumbiaUniversityMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "silo_CommercialSaleTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommercialSaleTerm", "terseLabel": "Commercial sale term" } } }, "localname": "CommercialSaleTerm", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "silo_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable" ], "xbrltype": "stringItemType" }, "silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable" ], "xbrltype": "stringItemType" }, "silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "stringItemType" }, "silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of milestone payments [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "stringItemType" }, "silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBfeesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of shall pay UMB fees [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleofshallpayUMBfeesLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable" ], "xbrltype": "stringItemType" }, "silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBfeesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of shall pay UMB fees [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleofshallpayUMBfeesTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable" ], "xbrltype": "stringItemType" }, "silo_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_CommonStockGrantDateFairValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock grant date fair value per share.", "label": "CommonStockGrantDateFairValuePerShare", "terseLabel": "Common stock grant date fair value per share (in Dollars per share)" } } }, "localname": "CommonStockGrantDateFairValuePerShare", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "perShareItemType" }, "silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares", "terseLabel": "Common stock issued for conversion of Series C preferred stock (in Shares)" } } }, "localname": "CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "silo_CommonStockIssuedForConversionOfSeriesCPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for conversion of Series C preferred stock.", "label": "CommonStockIssuedForConversionOfSeriesCPreferredStock", "terseLabel": "Common stock issued for conversion of Series C preferred stock" } } }, "localname": "CommonStockIssuedForConversionOfSeriesCPreferredStock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for conversion of Redeemable Series A Preferred Stock.", "label": "CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock", "terseLabel": "Common stock issued for conversion of Series C preferred stock" } } }, "localname": "CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "silo_CompanyPaidCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CompanyPaidCash", "terseLabel": "Company paid cash" } } }, "localname": "CompanyPaidCash", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_CompanyReceivedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Company received shares.", "label": "CompanyReceivedShares", "terseLabel": "Company received shares (in Shares)" } } }, "localname": "CompanyReceivedShares", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "sharesItemType" }, "silo_ConcentrationsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations (Details) [Line Items]" } } }, "localname": "ConcentrationsDetailsLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "silo_ConcentrationsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations (Details) [Table]" } } }, "localname": "ConcentrationsDetailsTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "silo_ConcentrationsRiskPercentage1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk percentage 1.", "label": "ConcentrationsRiskPercentage1", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationsRiskPercentage1", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "percentItemType" }, "silo_ConsiderationFeePayablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConsiderationFeePayablePercentage", "terseLabel": "Consideration fee payable percentage" } } }, "localname": "ConsiderationFeePayablePercentage", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "silo_ConsiderationInTheFormOfANoteReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consideration in the form of a note receivable.", "label": "ConsiderationInTheFormOfANoteReceivable", "terseLabel": "Consideration in the form of a note receivable" } } }, "localname": "ConsiderationInTheFormOfANoteReceivable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "silo_ConvertablePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertable preferred stock.", "label": "ConvertablePreferredStock", "terseLabel": "Converted preferred stock" } } }, "localname": "ConvertablePreferredStock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "silo_CostOfRevenuesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CostOfRevenuesPolicyTextBlock", "terseLabel": "Cost of Revenues" } } }, "localname": "CostOfRevenuesPolicyTextBlock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "silo_DeferredRevenueArrangementType_Domain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DeferredRevenueArrangementType_ [Domain]" } } }, "localname": "DeferredRevenueArrangementType_Domain", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "silo_DeferredRevenueLongtermPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "DeferredRevenueLongtermPortion", "terseLabel": "Revenue long term portion amounts" } } }, "localname": "DeferredRevenueLongtermPortion", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_DeferredRevenueLongtermPortionAmounted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue long-term portion amounted.", "label": "DeferredRevenueLongtermPortionAmounted", "terseLabel": "Deferred revenue long-term portion" } } }, "localname": "DeferredRevenueLongtermPortionAmounted", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_DiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DiscontinuedOperationsAbstract", "terseLabel": "DISCONTINUED OPERATIONS:" } } }, "localname": "DiscontinuedOperationsAbstract", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "silo_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_DrJamesKuoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DrJamesKuoMember", "terseLabel": "Dr. James Kuo [Member]" } } }, "localname": "DrJamesKuoMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "silo_EmploymentAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EmploymentAgreementDescription", "terseLabel": "Employment agreement, description" } } }, "localname": "EmploymentAgreementDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_EquityInvestmentsAtCost": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity investments, at cost.", "label": "EquityInvestmentsAtCost", "terseLabel": "Equity investments" } } }, "localname": "EquityInvestmentsAtCost", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "silo_EquityInvestmentsAtCostPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EquityInvestmentsAtCostPolicyTextBlock", "terseLabel": "Equity Investments, at Cost" } } }, "localname": "EquityInvestmentsAtCostPolicyTextBlock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "silo_EquityInvestmentsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "EquityInvestmentsAtFairValue", "terseLabel": "Equity investments consisting of common stock, at fair value" } } }, "localname": "EquityInvestmentsAtFairValue", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "silo_EquityInvestmentsAtFairValuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EquityInvestmentsAtFairValuePolicyTextBlock", "terseLabel": "Equity Investments, at Fair Value" } } }, "localname": "EquityInvestmentsAtFairValuePolicyTextBlock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "silo_EquityMethodInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "EquityMethodInvestment", "terseLabel": "Equity investments amount" } } }, "localname": "EquityMethodInvestment", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "silo_EquitySharesEarnedForServices": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity shares earned for services.", "label": "EquitySharesEarnedForServices", "terseLabel": "Equity shares earned for lock up agreement" } } }, "localname": "EquitySharesEarnedForServices", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) [Line Items]" } } }, "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]" } } }, "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Table]" } } }, "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) [Table]" } } }, "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "silo_FinanceLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance leases.", "label": "FinanceLeaseLiabilities", "negatedLabel": "Total liabilities" } } }, "localname": "FinanceLeaseLiabilities", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "silo_FirstCommercialSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First commercial sale.", "label": "FirstCommercialSale", "terseLabel": "First commercial sale" } } }, "localname": "FirstCommercialSale", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "silo_GrantedAsIncentivesAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "GrantedAsIncentivesAggregateIntrinsicValue", "terseLabel": "Granted as incentives, Aggregate Intrinsic Value" } } }, "localname": "GrantedAsIncentivesAggregateIntrinsicValue", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "monetaryItemType" }, "silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "GrantedAsIncentivesWeightedAverageRemainingContractualTermYears", "terseLabel": "Granted as incentives, Weighted Average Remaining Contractual Term (Years)" } } }, "localname": "GrantedAsIncentivesWeightedAverageRemainingContractualTermYears", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "durationItemType" }, "silo_GrossProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of Gross proceeds.", "label": "GrossProceeds", "terseLabel": "Gross proceeds" } } }, "localname": "GrossProceeds", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "silo_HomeBistroIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HomeBistroIncMember", "terseLabel": "Home Bistro, Inc. [Member]" } } }, "localname": "HomeBistroIncMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "silo_IncentiveStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IncentiveStockOptionMember", "terseLabel": "Incentive Stock Option [Member]" } } }, "localname": "IncentiveStockOptionMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInAssetsOfDiscontinuedOperation", "terseLabel": "Assets of discontinued operations" } } }, "localname": "IncreaseDecreaseInAssetsOfDiscontinuedOperation", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement.", "label": "IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree", "terseLabel": "Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement" } } }, "localname": "IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including Iniital fair value of stock options issued as stock-based compensation recorded as deferred compensation.", "label": "IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp", "terseLabel": "Iniital fair value of stock options issued as stock-based compensation recorded as deferred compensation" } } }, "localname": "IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "silo_InvestorInvestedAmountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "InvestorInvestedAmountPercentage", "terseLabel": "Subsequent financing, percentage" } } }, "localname": "InvestorInvestedAmountPercentage", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "silo_JVAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JVAgreementMember", "terseLabel": "JV Agreement [Member]" } } }, "localname": "JVAgreementMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "silo_LessNotesReceivableNetCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "LessNotesReceivableNetCurrentPortion", "terseLabel": "Less: notes receivable, net \u2013 current portion" } } }, "localname": "LessNotesReceivableNetCurrentPortion", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofnotesreceivablenetTable" ], "xbrltype": "monetaryItemType" }, "silo_LicenseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LicenseAgreementDescription", "terseLabel": "License agreement, description" } } }, "localname": "LicenseAgreementDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_LicenseAgreementExpire": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LicenseAgreementExpire", "terseLabel": "License agreement expire" } } }, "localname": "LicenseAgreementExpire", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "silo_LicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fee incurred and are directly related to generating license Expenses. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.", "label": "LicenseFee", "terseLabel": "License fee" } } }, "localname": "LicenseFee", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_LicenseFees": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License fees.", "label": "LicenseFees", "terseLabel": "LICENSE FEE REVENUES:" } } }, "localname": "LicenseFees", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "silo_LicensorShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LicensorShare", "terseLabel": "Licensor share (in Shares)" } } }, "localname": "LicensorShare", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "silo_LiquidityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LiquidityPolicyTextBlock", "terseLabel": "Liquidity" } } }, "localname": "LiquidityPolicyTextBlock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "silo_MasterLincenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MasterLincenseAgreementMember", "terseLabel": "Master License Agreement [Member]" } } }, "localname": "MasterLincenseAgreementMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "silo_Milestone": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Milestone", "terseLabel": "Milestone" } } }, "localname": "Milestone", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "stringItemType" }, "silo_MilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "MilestonePayment", "terseLabel": "Payment" } } }, "localname": "MilestonePayment", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "monetaryItemType" }, "silo_MinimumAnnualRoyalty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of minimum anual royalty.", "label": "MinimumAnnualRoyalty", "terseLabel": "Minimum Annual Royalty" } } }, "localname": "MinimumAnnualRoyalty", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable" ], "xbrltype": "monetaryItemType" }, "silo_NetAssetOfNFIDBusinessDisposed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net asset of NFID business disposed.", "label": "NetAssetOfNFIDBusinessDisposed", "terseLabel": "Net asset of NFID business disposed" } } }, "localname": "NetAssetOfNFIDBusinessDisposed", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "silo_NetSalePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NetSalePercentage", "terseLabel": "Net sale percentage" } } }, "localname": "NetSalePercentage", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "silo_NonrefundableCashPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "NonrefundableCashPayment", "terseLabel": "Non-refundable cash payment" } } }, "localname": "NonrefundableCashPayment", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_NotesReceivableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable (Details) [Line Items]" } } }, "localname": "NotesReceivableDetailsLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "stringItemType" }, "silo_NotesReceivableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable (Details) [Table]" } } }, "localname": "NotesReceivableDetailsTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "stringItemType" }, "silo_NumberOfVotingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumberOfVotingShares", "terseLabel": "Number of voting shares (in Shares)" } } }, "localname": "NumberOfVotingShares", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "silo_OmnibusEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OmnibusEquityIncentivePlanMember", "terseLabel": "Omnibus Equity incentive Plan [Member]" } } }, "localname": "OmnibusEquityIncentivePlanMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "silo_OneLicenseeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OneLicenseeMember", "terseLabel": "One Licensee [Member]" } } }, "localname": "OneLicenseeMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "silo_OneLicensorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OneLicensorMember", "terseLabel": "One Licensor [Member]" } } }, "localname": "OneLicensorMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "silo_OrganizationandBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Business (Details) [Table]" } } }, "localname": "OrganizationandBusinessDetailsTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "silo_OtherDepreciationsAndAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "OtherDepreciationsAndAmortization", "terseLabel": "Recognized amortization expenses" } } }, "localname": "OtherDepreciationsAndAmortization", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_PaymentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentDescription", "terseLabel": "Payment description" } } }, "localname": "PaymentDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable" ], "xbrltype": "stringItemType" }, "silo_PaymentEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentEightMember", "terseLabel": "Payment Three [Member]" } } }, "localname": "PaymentEightMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable" ], "xbrltype": "domainItemType" }, "silo_PaymentFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentFiveMember", "terseLabel": "Payment Five [Member]" } } }, "localname": "PaymentFiveMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable", "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "domainItemType" }, "silo_PaymentFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentFourMember", "terseLabel": "Payment Four [Member]" } } }, "localname": "PaymentFourMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable", "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "domainItemType" }, "silo_PaymentOfUniversity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "PaymentOfUniversity", "terseLabel": "Payment of university" } } }, "localname": "PaymentOfUniversity", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_PaymentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentOneMember", "terseLabel": "Payment One [Member]" } } }, "localname": "PaymentOneMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable", "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "domainItemType" }, "silo_PaymentSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentSevenMember", "terseLabel": "Payment Two [Member]" } } }, "localname": "PaymentSevenMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable" ], "xbrltype": "domainItemType" }, "silo_PaymentSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentSixMember", "terseLabel": "Payment One [Member]" } } }, "localname": "PaymentSixMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable" ], "xbrltype": "domainItemType" }, "silo_PaymentThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentThreeMember", "terseLabel": "Payment Three [Member]" } } }, "localname": "PaymentThreeMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable", "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "domainItemType" }, "silo_PaymentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentTwoMember", "terseLabel": "Payment Two [Member]" } } }, "localname": "PaymentTwoMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable", "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "domainItemType" }, "silo_PlacementAgentWarrantsDescriptoin": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PlacementAgentWarrantsDescriptoin", "terseLabel": "Placement agent warrants, description" } } }, "localname": "PlacementAgentWarrantsDescriptoin", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "silo_PlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PlacementAgentWarrantsMember", "terseLabel": "Placement Agent Warrants [Member]" } } }, "localname": "PlacementAgentWarrantsMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "silo_PreferredStockStatedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of preferred stock stated value.", "label": "PreferredStockStatedValue", "terseLabel": "Preferred stock, stated value (in Dollars)" } } }, "localname": "PreferredStockStatedValue", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "silo_PrincipalBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of principal balance.", "label": "PrincipalBalance", "terseLabel": "Note receivable - non current" } } }, "localname": "PrincipalBalance", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails" ], "xbrltype": "monetaryItemType" }, "silo_PromissoryNote": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PromissoryNote", "terseLabel": "Promissory note interest" } } }, "localname": "PromissoryNote", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "percentItemType" }, "silo_PromissoryNoteAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Promissory note agreement.", "label": "PromissoryNoteAgreement", "terseLabel": "Promissory note agreement note deposit and credit towards acquisition" } } }, "localname": "PromissoryNoteAgreement", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "silo_PromissoryNoteReceivableAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PromissoryNoteReceivableAgreementMember", "terseLabel": "Promissory Note Receivable Agreement [Member]", "verboseLabel": "Promissory note receivable agreement [Member]" } } }, "localname": "PromissoryNoteReceivableAgreementMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "silo_PromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of promissory notes.", "label": "PromissoryNotes", "terseLabel": "Promissory Notes" } } }, "localname": "PromissoryNotes", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails" ], "xbrltype": "monetaryItemType" }, "silo_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PurchaseAgreementMember", "terseLabel": "Purchase Agreement [Member]" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "silo_PurchaseAgreementsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase agreement, description.", "label": "PurchaseAgreementsDescription", "terseLabel": "Purchase agreement, description" } } }, "localname": "PurchaseAgreementsDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "silo_PurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase price.", "label": "PurchasePrice", "terseLabel": "Purchase price" } } }, "localname": "PurchasePrice", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails" ], "xbrltype": "monetaryItemType" }, "silo_PursuantTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pursuant Terms.", "label": "PursuantTerms", "terseLabel": "Pursuant terms, description" } } }, "localname": "PursuantTerms", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_ReceivedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company received shares.", "label": "ReceivedShares", "terseLabel": "Received shares (in Shares)" } } }, "localname": "ReceivedShares", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "sharesItemType" }, "silo_RecognizedRevenues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "RecognizedRevenues", "terseLabel": "Recognized revenues" } } }, "localname": "RecognizedRevenues", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_RecoveredAggregateBadDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Recovered aggregate bad debt.", "label": "RecoveredAggregateBadDebt", "terseLabel": "Recovered aggregate bad debt" } } }, "localname": "RecoveredAggregateBadDebt", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "silo_RecoveredBadDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value recovered bad debt", "label": "RecoveredBadDebt", "terseLabel": "Recovered bad debt" } } }, "localname": "RecoveredBadDebt", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "silo_RemainsCollectibleSettlementAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remains Collectible Settlement Agreement.", "label": "RemainsCollectibleSettlementAgreement", "terseLabel": "Remains collectible settlement agreement" } } }, "localname": "RemainsCollectibleSettlementAgreement", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "silo_RemainsCollectibleSettlementAgreementAmountReserved": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remains collectible settlement agreement amount reserved.", "label": "RemainsCollectibleSettlementAgreementAmountReserved", "terseLabel": "Remains collectible settlement agreement amount reserved" } } }, "localname": "RemainsCollectibleSettlementAgreementAmountReserved", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "silo_RevenueTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RevenueTerm", "terseLabel": "Revenue term" } } }, "localname": "RevenueTerm", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "silo_ReverseStockSplitVoteDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ReverseStockSplitVoteDescription", "terseLabel": "Reverse stock split vote, description" } } }, "localname": "ReverseStockSplitVoteDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_RoyaltyPaymentsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RoyaltyPaymentsDescription", "terseLabel": "Royalty payments, description" } } }, "localname": "RoyaltyPaymentsDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of activity in the company\u2019s equity investments, at fair value [Abstract]" } } }, "localname": "ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock", "terseLabel": "Schedule of activity in the company\u2019s equity investments, at fair value" } } }, "localname": "ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of anti-dilutive net loss per share [Abstract]" } } }, "localname": "ScheduleOfAntiDilutiveNetLossPerShareAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assets and liabilities measured at fair value on a recurring basis [Abstract]" } } }, "localname": "ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tablular disclosure of schedule of anti-dilutive net loss per share.", "label": "ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock", "terseLabel": "Schedule of anti-dilutive net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of financial data of the company\u2019s gain from sale of the NFID business [Abstract]" } } }, "localname": "ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfMilestonePayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of milestone payments.", "label": "ScheduleOfMilestonePayments", "terseLabel": "Schedule of milestone payments" } } }, "localname": "ScheduleOfMilestonePayments", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "silo_ScheduleOfMilestonePaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of milestone payments [Abstract]" } } }, "localname": "ScheduleOfMilestonePaymentsAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfNotesReceivableNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of notes receivable net [Abstract]" } } }, "localname": "ScheduleOfNotesReceivableNetAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of operating result of discontinued operations of the NFID business [Abstract]" } } }, "localname": "ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfShallPayUMB": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of shall pay UMB.", "label": "ScheduleOfShallPayUMB", "terseLabel": "Schedule of shall pay UMB fees" } } }, "localname": "ScheduleOfShallPayUMB", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "silo_ScheduleOfShallPayUmbFeesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of shall pay UMB fees [Abstract]" } } }, "localname": "ScheduleOfShallPayUmbFeesAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfStockOptionsActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of stock options activities [Abstract]" } } }, "localname": "ScheduleOfStockOptionsActivitiesAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfUMBMinimumRoyaltyPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of UMB minimum royalty payments.", "label": "ScheduleOfUMBMinimumRoyaltyPayments", "terseLabel": "Schedule of UMB minimum royalty payments" } } }, "localname": "ScheduleOfUMBMinimumRoyaltyPayments", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of UMB minimum royalty payments [Abstract]" } } }, "localname": "ScheduleOfUmbMinimumRoyaltyPaymentsAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_ScheduleOfWarrantActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrant activities [Abstract]" } } }, "localname": "ScheduleOfWarrantActivitiesAbstract", "nsuri": "http://silopharma.com/20220630", "xbrltype": "stringItemType" }, "silo_SecuritiesReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "SecuritiesReceived", "terseLabel": "Securities received" } } }, "localname": "SecuritiesReceived", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_SeriesCConversionPriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesCConversionPriceMember", "terseLabel": "Series C Conversion Price [Member]" } } }, "localname": "SeriesCConversionPriceMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "silo_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesCConvertiblePreferredStockMember", "terseLabel": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "silo_SeriesCPurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesCPurchaseAgreementsMember", "terseLabel": "Series C Purchase Agreements [Member]" } } }, "localname": "SeriesCPurchaseAgreementsMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of option outstanding.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue", "periodEndLabel": "Aggregate Intrinsic Value, ending balance", "periodStartLabel": "Aggregate Intrinsic Value, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "monetaryItemType" }, "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of aggregated intrinsic value for forfeited shares.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue", "terseLabel": "Aggregate Intrinsic Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "monetaryItemType" }, "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of aggregate intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "terseLabel": "Granted pursuant to employment agreement, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "monetaryItemType" }, "silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock warrants outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "ShareBasedComponsationNumberOfWarrantsExercisableinDollars", "terseLabel": "Number of Warrants, Exercisable" } } }, "localname": "ShareBasedComponsationNumberOfWarrantsExercisableinDollars", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "sharesItemType" }, "silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted", "terseLabel": "Granted/Forfeited, Weighted Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "durationItemType" }, "silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable", "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable" } } }, "localname": "ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "durationItemType" }, "silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm", "terseLabel": "Weighted Average Remaining Contractual Term (Years), Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "durationItemType" }, "silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "terseLabel": "Granted pursuant to employment agreement, Weighted Average Remaining Contractual Term (Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "durationItemType" }, "silo_SponsoredPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of sponsored payment.", "label": "SponsoredPayment", "terseLabel": "Payment" } } }, "localname": "SponsoredPayment", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable" ], "xbrltype": "monetaryItemType" }, "silo_SponsoredResearchAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SponsoredResearchAgreementDescription", "terseLabel": "Sponsored research agreement, description" } } }, "localname": "SponsoredResearchAgreementDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_SponsoredStudyAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SponsoredStudyAgreementDescription", "terseLabel": "Sponsored study agreement, description" } } }, "localname": "SponsoredStudyAgreementDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockOptionsMember", "terseLabel": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "domainItemType" }, "silo_StockholdersEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Details) [Line Items]" } } }, "localname": "StockholdersEquityDetailsLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Details) - Schedule of stock options activities [Line Items]" } } }, "localname": "StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "stringItemType" }, "silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Details) - Schedule of stock options activities [Table]" } } }, "localname": "StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "stringItemType" }, "silo_StockholdersEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Details) [Table]" } } }, "localname": "StockholdersEquityDetailsTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "silo_SublicenseAgreementAmountPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "SublicenseAgreementAmountPaid", "terseLabel": "Sublicense agreement amount paid" } } }, "localname": "SublicenseAgreementAmountPaid", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_SublicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SublicenseAgreementMember", "terseLabel": "Sublicense Agreement [Member]" } } }, "localname": "SublicenseAgreementMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "silo_SublicenseAmountPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sublicense amount paid.", "label": "SublicenseAmountPaid", "terseLabel": "Sublicense amount paid" } } }, "localname": "SublicenseAmountPaid", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_SublicenseIncomeDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SublicenseIncomeDescription", "terseLabel": "Sublicense income, description" } } }, "localname": "SublicenseIncomeDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_SublicenseIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage sublicense income.", "label": "SublicenseIncomePercentage", "terseLabel": "Sublicense income, percentage" } } }, "localname": "SublicenseIncomePercentage", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable" ], "xbrltype": "stringItemType" }, "silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable" ], "xbrltype": "stringItemType" }, "silo_TypeOfAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypeOfAgreementAxis", "terseLabel": "Type of Agreement [Axis]" } } }, "localname": "TypeOfAgreementAxis", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "silo_TypeOfAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypeOfAgreement [Domain]" } } }, "localname": "TypeOfAgreementDomain", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "silo_TypesOfAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypesOfAgreementAxis", "terseLabel": "Type of Agreement [Axis]" } } }, "localname": "TypesOfAgreementAxis", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "stringItemType" }, "silo_TypesOfAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypesOfAgreement [Domain]" } } }, "localname": "TypesOfAgreementDomain", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "silo_UnrealizedGainLossOnEquityInvestments": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net unrealized gain (loss) on equity investments (non-controlled/non-affiliated investments).", "label": "UnrealizedGainLossOnEquityInvestments", "terseLabel": "Net unrealized gain (loss) on equity investments" } } }, "localname": "UnrealizedGainLossOnEquityInvestments", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "silo_UpfrontLicenseFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upfront license fees.", "label": "UpfrontLicenseFees", "terseLabel": "Upfront license fees" } } }, "localname": "UpfrontLicenseFees", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_VendorConcentrationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "VendorConcentrationsMember", "terseLabel": "Vendor Concentrations [Member]" } } }, "localname": "VendorConcentrationsMember", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "silo_WarrantsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsTerm", "terseLabel": "Warrants term" } } }, "localname": "WarrantsTerm", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "silo_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of working capital.", "label": "WorkingCapital", "terseLabel": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "silo_YearsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "YearsDescription", "terseLabel": "Years" } } }, "localname": "YearsDescription", "nsuri": "http://silopharma.com/20220630", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable" ], "xbrltype": "stringItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Leader of board of directors.", "label": "Board of Directors Chairman [Member]", "terseLabel": "Board Granted [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r167", "r270", "r271", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r204", "r205", "r206", "r207", "r223", "r249", "r283", "r284", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r440", "r442", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r204", "r205", "r206", "r207", "r223", "r249", "r283", "r284", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r440", "r442", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r167", "r270", "r271", "r441" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r200", "r204", "r205", "r206", "r207", "r223", "r249", "r273", "r283", "r284", "r315", "r316", "r317", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r440", "r442", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r200", "r204", "r205", "r206", "r207", "r223", "r249", "r273", "r283", "r284", "r315", "r316", "r317", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r440", "r442", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "auth_ref": [ "r107", "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Condensed Balance Sheet [Table Text Block]", "terseLabel": "Schedule of financial data of the company\u2019s gain from sale of the NFID business" } } }, "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables" ], "xbrltype": "textBlockItemType" }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "auth_ref": [ "r107", "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table Text Block]", "terseLabel": "Schedule of operating result of discontinued operations of the NFID business" } } }, "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessTables" ], "xbrltype": "textBlockItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r168", "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r43", "r106", "r377", "r379" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r33", "r382" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r109", "r110", "r111", "r323", "r324", "r325", "r354" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based Compensation (in Dollars)", "verboseLabel": "Stock-based Compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r39", "r177", "r189", "r190", "r192" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful account and bad debt" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of recovery of loans and lease receivables which had previously been fully or partially written-off as bad debts.", "label": "Allowance for Loan and Lease Loss, Recovery of Bad Debts", "terseLabel": "Received payment" } } }, "localname": "AllowanceForLoanAndLeaseLossRecoveryOfBadDebts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r21", "r104", "r158", "r161", "r165", "r187", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r342", "r347", "r363", "r380", "r382", "r410", "r427" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r13", "r42", "r104", "r187", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r342", "r347", "r363", "r380", "r382" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Principles of consolidation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Organization and Business [Line items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Total assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Business [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r11", "r18", "r91" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r84", "r91", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS - end of the period", "periodStartLabel": "CASH AND CASH EQUIVALENTS - beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r84", "r364" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Federal deposit insurance corporation" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r27", "r29", "r30", "r101", "r104", "r125", "r126", "r131", "r134", "r136", "r142", "r143", "r144", "r187", "r209", "r213", "r214", "r215", "r218", "r219", "r246", "r247", "r251", "r255", "r261", "r363", "r459" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable", "http://silopharma.com/role/ShareholdersEquityType2or3", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Warrant to purchase shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Granted warrants to purchase shares" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r268", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r416", "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitment and Contingencies (see Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r201", "r202", "r203", "r208", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares of common stock reserved and avail for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r109", "r110", "r354" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r30", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r30", "r382" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 500,000,000 shares authorized; 99,395,304 and 98,636,970 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r150", "r151", "r167", "r361", "r362", "r451" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r150", "r151", "r167", "r361", "r362", "r448", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r150", "r151", "r167", "r361", "r362", "r448", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "CONCENTRATIONS" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/Concentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r150", "r151", "r167", "r361", "r362", "r451" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionContractorLiquidityCharacteristic": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Description of liquidity characteristic of construction contractor's asset and liability.", "label": "Construction Contractor, Liquidity Characteristic", "terseLabel": "Liquidity damage, description" } } }, "localname": "ConstructionContractorLiquidityCharacteristic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Convertible common stock" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "auth_ref": [ "r28", "r29", "r262", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for preferred stock.", "label": "Preferred Stock, Convertible, Terms", "terseLabel": "Convertible preferred stock, description" } } }, "localname": "ConvertiblePreferredStockTermsOfConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r72", "r104", "r187", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r363" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "COST OF REVENUES" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r149", "r167" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRefundableFeesProceeds": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from customers for revenue related transactions that are refundable to the customers and do not meet the criteria for revenue recognition.", "label": "Customer Refundable Fees, Proceeds", "terseLabel": "Non refundable fees" } } }, "localname": "CustomerRefundableFeesProceeds", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r94", "r96" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofshallpayUMBfeesTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r23", "r24", "r103", "r107", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r372", "r411", "r412", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable", "http://silopharma.com/role/ScheduleofmilestonepaymentsTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r222", "r237" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price per share (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r220", "r238", "r239", "r371", "r372", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal balance" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "terseLabel": "Increased interest rate per annum" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r48", "r221" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Accrued interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r49", "r223", "r359" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Expired term" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).", "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense", "terseLabel": "Deferred compensation balance (in Dollars)", "verboseLabel": "Deferred compensation balance" } } }, "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "auth_ref": [ "r272", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Compensation Expense", "terseLabel": "Fair value of the unvested stock options (in Dollars)", "verboseLabel": "Fair value of the unvested stock option" } } }, "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Offering expenses (in Dollars)" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue - current portion" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue - long-term portion" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Recognized revenues" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Interest rate per annum percentage" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r62", "r433" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Loss from discontinued operations, net of tax" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r8", "r329", "r336", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "terseLabel": "Loss from discontinued operations" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r7", "r9" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "auth_ref": [ "r7", "r9" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "terseLabel": "Gross profit (loss)" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r10", "r199" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "DISPOSAL OF THE DISCONTINUED OPERATIONS OF THE NFID BUSINESS" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPreferredStockCash": { "auth_ref": [ "r267", "r424" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.", "label": "Dividends, Preferred Stock, Cash", "terseLabel": "Deemed dividend (in Dollars)" } } }, "localname": "DividendsPreferredStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "NET LOSS PER COMMON SHARE:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r64", "r114", "r115", "r116", "r117", "r118", "r123", "r125", "r134", "r135", "r136", "r139", "r140", "r355", "r356", "r421", "r435" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Continuing operations - basic and diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r64", "r114", "r115", "r116", "r117", "r118", "r125", "r134", "r135", "r136", "r139", "r140", "r355", "r356", "r421", "r435" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Discontinued operations - basic and diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r57", "r58", "r59", "r109", "r110", "r111", "r113", "r119", "r121", "r141", "r188", "r261", "r267", "r323", "r324", "r325", "r334", "r335", "r354", "r365", "r366", "r367", "r368", "r369", "r370", "r374", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r19", "r159", "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of excess stock shares permitted to be issued.", "label": "Excess Stock, Shares Authorized", "terseLabel": "Shares authorized" } } }, "localname": "ExcessStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FDICIndemnificationAssetCashPaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decreases to the indemnification asset due to cash payments received relating to loss sharing agreements with the Federal Deposit Insurance Corporation (FDIC).", "label": "FDIC Indemnification Asset, Cash Payments Received", "terseLabel": "FDIC cash limits" } } }, "localname": "FDICIndemnificationAssetCashPaymentsReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r229", "r238", "r239", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r358", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r229", "r274", "r275", "r280", "r282", "r358", "r383" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r229", "r238", "r239", "r274", "r275", "r280", "r282", "r358", "r384" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r229", "r238", "r239", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r358", "r385" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r39", "r173", "r189", "r190", "r192", "r414", "r461", "r463", "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, Allowance for Credit Loss", "negatedLabel": "Less: allowance for doubtful accounts" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofnotesreceivablenetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r74", "r89", "r183" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "terseLabel": "Net realized loss on equity investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "terseLabel": "Gain from sale of NFID business" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainOnSaleOfInvestments": { "auth_ref": [ "r67", "r68", "r89", "r418", "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.", "label": "Gain on Sale of Investments", "terseLabel": "Equity investment Sold" } } }, "localname": "GainOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r89", "r242", "r243" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Gain on forgiveness of PPP note payable" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnRestructuringOfDebt": { "auth_ref": [ "r244" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.", "label": "Gains (Losses) on Restructuring of Debt", "negatedLabel": "Gain on forgiveness of PPP note payable and accrued interest" } } }, "localname": "GainsLossesOnRestructuringOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralInsuranceExpense": { "auth_ref": [ "r73" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).", "label": "General Insurance Expense", "terseLabel": "Insurance expense" } } }, "localname": "GeneralInsuranceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r69", "r104", "r158", "r160", "r163", "r164", "r166", "r187", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r363" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r70", "r90", "r114", "r115", "r116", "r117", "r132", "r136", "r340" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "LOSS FROM CONTINUING OPERATIONS" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r60", "r158", "r160", "r163", "r164", "r166", "r408", "r419", "r423", "r437" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r8", "r341" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "totalLabel": "LOSS FROM DISCONTINUED OPERATIONS" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r61", "r89", "r156", "r186", "r417", "r432" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Net realized gain on equity investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r120", "r121", "r157", "r329", "r336", "r337", "r438" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r56", "r327", "r328", "r330", "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r88" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPayablesToBrokerDealers": { "auth_ref": [ "r88" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations incurred arising from transactions with broker-dealers, such as amounts due on margin and unsettled cash transactions; includes payables to brokers, dealers and clearing organizations.", "label": "Increase (Decrease) in Payable to Broker-Dealer and Clearing Organization", "terseLabel": "Insurance payable" } } }, "localname": "IncreaseDecreaseInPayablesToBrokerDealers", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r88" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r88" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Interest receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r422" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r82", "r86", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet": { "auth_ref": [ "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all derivatives not designated as hedging instruments.", "label": "Interest Rate Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net", "terseLabel": "Common stock grant date fair value" } } }, "localname": "InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableNoncurrent": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of noncurrent interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable, Noncurrent", "terseLabel": "Interest receivable (in Dollars)" } } }, "localname": "InterestReceivableNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r12", "r40", "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentMaturityDate": { "auth_ref": [ "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of investment, in YYYY-MM-DD format.", "label": "Investment Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "InvestmentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LayawaySaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of deferred revenue by arrangement wherein a retail customer pays installments of cash over a period of time, which will generally be taken into income upon delivery to the customer, and typically upon payment of the final installment.", "label": "Layaway Sale [Member]", "terseLabel": "Six-monthly installments [Member]" } } }, "localname": "LayawaySaleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r104", "r162", "r187", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r343", "r347", "r348", "r363", "r380", "r381" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r38", "r104", "r187", "r363", "r382", "r413", "r430" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r47", "r104", "r187", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r343", "r347", "r348", "r363", "r380", "r381", "r382" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r15", "r16", "r17", "r24", "r25", "r104", "r187", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r343", "r347", "r348", "r363", "r380", "r381" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total Long Term Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG TERM LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "NOTES RECEIVABLE" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Insurance payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for bad debt, of increase (decrease) in loan receivables held-for-sale that are not part of a disposal group.", "label": "Loans Receivable Held-for-sale, Reconciliation to Cash Flow, Period Increase (Decrease)", "terseLabel": "Bad debt allowance" } } }, "localname": "LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturityDate": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format.", "label": "Long-Term Debt, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "LongTermDebtMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails", "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate", "terseLabel": "Bearing interest rate percentage" } } }, "localname": "LongTermDebtPercentageBearingVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNFIDBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized (loss) gain" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInContinuingOperations": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.", "label": "Net Cash Provided by (Used in) Continuing Operations", "terseLabel": "Cash in operations" } } }, "localname": "NetCashProvidedByUsedInContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH PROVIDED BY INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r87", "r90" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r9", "r54", "r55", "r59", "r63", "r90", "r104", "r112", "r114", "r115", "r116", "r117", "r120", "r121", "r132", "r158", "r160", "r163", "r164", "r166", "r187", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r356", "r363", "r420", "r434" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "NET LOSS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow", "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r54", "r55", "r59", "r120", "r121", "r345", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r124", "r127", "r128", "r129", "r130", "r133", "r136" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "NET LOSS AVAILABLE TO COMMON STOCKHOLDERS" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSE):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r169", "r170", "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Principal balance" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r32", "r179", "r189", "r193", "r194", "r195", "r196", "r460", "r461", "r462" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Financing Receivable, before Allowance for Credit Loss", "terseLabel": "Principal amounts of notes receivable" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofnotesreceivablenetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r169", "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Notes receivable \u2013 non-current" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofnotesreceivablenetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r158", "r160", "r163", "r164", "r166" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "OPERATING LOSS FROM CONTINUING OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r108", "r122", "r155", "r351" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "ORGANIZATION AND BUSINESS" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/OrganizationandBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r20" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Note receivable - non-current, including interest receivable of $3,590" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.", "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent", "terseLabel": "Issuance of deferred compensation balance (in Dollars)" } } }, "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r439" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income from equity shares earned for lock up agreement" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedLabel": "Total operating and other non-operating expenses" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r41", "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expense and other current assets" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Total Notes receivable, net" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofnotesreceivablenetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireReceivables": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of all receivables.", "label": "Payments to Acquire Receivables", "terseLabel": "Total receivable" } } }, "localname": "PaymentsToAcquireReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r29", "r262" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred Stock, Conversion Basis", "terseLabel": "Preferred stock conversion, description" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred Stock, Convertible, Shares Issuable", "terseLabel": "Designated shares of preferred stock" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "negatedLabel": "Deemed dividend" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r29", "r246" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r245", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred Stock, Redemption Price Per Share", "terseLabel": "Preferred stock redemption price per share (in Dollars per share)" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r29", "r246" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Share issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "verboseLabel": "Share outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r29", "r382" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets - current" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "auth_ref": [ "r21", "r409", "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Noncurrent", "terseLabel": "Prepaid expenses and other current assets \u2013 non-current" } } }, "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r20" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense, Noncurrent", "terseLabel": "Prepaid expenses - non-current" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseOtherNoncurrent": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense Other, Noncurrent", "terseLabel": "Prepaid expenses non-current" } } }, "localname": "PrepaidExpenseOtherNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r80" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Net proceeds from sale of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Warrant value (in Dollars)" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "negatedLabel": "Sales at original cost" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "auth_ref": [ "r77" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Proceeds from Sale of Equity Method Investments", "terseLabel": "Net proceeds from sale of equity investments" } } }, "localname": "ProceedsFromSaleOfEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Product sales, net" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r449", "r450" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r9", "r54", "r55", "r59", "r83", "r104", "r112", "r120", "r121", "r158", "r160", "r163", "r164", "r166", "r187", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r341", "r344", "r346", "r349", "r350", "r356", "r363", "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r65", "r191" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt recovery" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RecognitionOfDeferredRevenue": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.", "label": "Recognition of Deferred Revenue", "terseLabel": "Deferred revenue current portion" } } }, "localname": "RecognitionOfDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of recorded unconditional purchase obligation to be paid in remainder of current fiscal year.", "label": "Recorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year", "terseLabel": "Company paid second payment" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r281", "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r281", "r375", "r379", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r81" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayment of advance from a related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r326", "r394", "r455" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development cost" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement", "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r35", "r267", "r382", "r429", "r446", "r447" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r109", "r110", "r111", "r113", "r119", "r121", "r188", "r323", "r324", "r325", "r334", "r335", "r354", "r443", "r445" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsUnappropriated": { "auth_ref": [ "r34", "r102", "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is available for dividend distribution. Earnings not paid out as dividends but instead reinvested in the core business or used to pay off debt. Unappropriated profit is part of shareholder equity. Also called cumulative distributions or earned surplus or accumulated earnings or unappropriated profit.", "label": "Retained Earnings, Unappropriated", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsUnappropriated", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Gross proceeds (in Dollars)" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of aggregate shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of notes receivable net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r293", "r308", "r311" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock options activities" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r268", "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of warrant activities" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r27", "r29", "r261" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock [Member]", "verboseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r27", "r29", "r261" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Convertible Preferred Stock [Member]", "netLabel": "Series B", "terseLabel": "Series B Preferred Stock [Member]", "verboseLabel": "Series B Convertible Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/ShareholdersEquityType2or3", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r27", "r29", "r261" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Convertible Preferred Stock [Member]", "netLabel": "Series C", "terseLabel": "Series C Preferred Stock [Member]", "verboseLabel": "Series C Convertible Preferred Stock" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable", "http://silopharma.com/role/ShareholdersEquityType2or3", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://silopharma.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r287", "r289" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "terseLabel": "Employment agreement, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted/Forfeited, Number of Warrants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Warrants, ending balance", "periodStartLabel": "Number of Warrants, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Exercise Price, ending balance", "periodStartLabel": "Weighted Average Exercise Price, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date price per warrant (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Options, Exercisable," } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable", "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Number of Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Granted pursuant to employment agreement, Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted as incentives, Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, balance ending", "periodStartLabel": "Aggregate Intrinsic Value, balance beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options, balance ending", "periodStartLabel": "Number of Options, beginning balance outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, balance ending", "periodStartLabel": "Weighted Average Exercise Price, balance beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "terseLabel": "Stock option", "verboseLabel": "Stock option (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted pursuant to employment agreement, Weighted Average Exercise Price", "verboseLabel": "Granted/Forfeited, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable", "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price", "terseLabel": "Granted as incentives, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": { "auth_ref": [ "r285", "r286", "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.", "label": "Share-Based Payment Arrangement, Forfeiture [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationForfeituresPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.", "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable", "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (Years), balance ending", "verboseLabel": "Weighted Average Remaining Contractual Term (Years), ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable", "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (Years), balance beginning", "verboseLabel": "Weighted Average Remaining Contractual Term (Years), beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable", "http://silopharma.com/role/ScheduleofwarrantactivitiesTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of stock option (in Dollars)", "verboseLabel": "Fair value of stock option" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Fair value of unvested stock option" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r98", "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r27", "r29", "r30", "r101", "r104", "r125", "r126", "r131", "r134", "r136", "r142", "r143", "r144", "r187", "r209", "r213", "r214", "r215", "r218", "r219", "r246", "r247", "r251", "r255", "r261", "r363", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable", "http://silopharma.com/role/ShareholdersEquityType2or3", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r52", "r57", "r58", "r59", "r109", "r110", "r111", "r113", "r119", "r121", "r141", "r188", "r261", "r267", "r323", "r324", "r325", "r334", "r335", "r354", "r365", "r366", "r367", "r368", "r369", "r370", "r374", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable", "http://silopharma.com/role/ScheduleofwarrantactivitiesTable", "http://silopharma.com/role/ShareholdersEquityType2or3", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r109", "r110", "r111", "r141", "r395" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of preferred stock and warrants for common stock issued.", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "terseLabel": "Deemed dividend upon issuance of preferred stock" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Common stock warrants granted for services" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Series C preferred stock issued for cash, net of offering cost (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r29", "r30", "r261", "r267", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Aggregate of incentive stock options" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common stock warrants granted for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Series C preferred stock issued for cash, net of offering cost" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r29", "r30", "r267", "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock options issued as stock based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r52", "r261", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option value (in Dollars)" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r30", "r36", "r37", "r104", "r180", "r187", "r363", "r382" ], "calculation": { "http://silopharma.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet", "http://silopharma.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r102", "r247", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r267", "r269", "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Supplemental Deferred Purchase Price", "terseLabel": "Aggregate purchase price" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/NotesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for agreement to continue an employee's salary after termination of employment (but before retirement) including death, disability, or other event. For example, a company may agree to continue a disabled employee's salary for six months.", "label": "Supplemental Unemployment Benefits, Salary Continuation", "terseLabel": "Salary was increased" } } }, "localname": "SupplementalUnemploymentBenefitsSalaryContinuation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r171", "r172", "r175", "r176", "r178", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Notes Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r89" ], "calculation": { "http://silopharma.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Net unrealized loss (gain) loss on equity investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r145", "r146", "r147", "r148", "r152", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense for depreciation and amortization of regulated operation.", "label": "Utilities Operating Expense, Depreciation and Amortization", "terseLabel": "Amortization expense" } } }, "localname": "UtilitiesOperatingExpenseDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]", "verboseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable", "http://silopharma.com/role/ScheduleofwarrantactivitiesTable", "http://silopharma.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r124", "r136" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Basic and diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://silopharma.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r10": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(4)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(m)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3)(ii))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991581-234733" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4)(ii))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r457": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r458": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r459": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1404" }, "r461": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)" }, "r462": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)" }, "r463": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(3)" }, "r464": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405" }, "r465": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r466": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" } }, "version": "2.1" }